A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
NCT01151540, EU CTR 2016-004953-34
Nov 2010 - Aug 2013
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide [ Time Frame: From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 years 10 months ]
The CSR synopses contained on this website are from clinical trials sponsored by Eisai and are provided for informational purposes only. These summaries contain data from the specific study population but do not include the patient-level data from each study participant. The results reported in any single trial may not reflect the overall potential risks or benefits associated with Eisai’s products.
Only health care professionals may determine if a specific product is appropriate as a treatment option for a particular patient. Health care professionals should refer to the specific labelling information approved in their country when making prescribing decisions.
The information provided is not intended to commercialize or promote Eisai’s products for any unapproved uses.
All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information contained on this website. Eisai reserves the right to amend any information on this website at any time at its sole discretion.
No download available
Publication reference citation
Ohtsuka Y et al. Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: An open-label study following a randomized clinical trial. Epilepsy Research 2016; 121: 1-7. DOI: http://dx.doi.org/10.1016/j.eplepsyres.2016.01.002
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
Redacted documents are available upon request for this study.